RecruitingNCT07409584

Mental Health and Suicidality in Glioblastoma Patients in Germany

Mental Health and Suicidality in Glioblastoma Patients in Germany - a Multicenter Observational Study (SHINE-GLIO Study)

Sponsor

University Hospital, Essen

Enrollment

176 participants

Start Date

Mar 18, 2026

Study Type

OBSERVATIONAL

Conditions

Glioblastoma (GBM)

Summary

The aim of the study is to use standardized questionnaires to systematically record influencing factors or predictors for suicidal behavior in glioblastoma patients, particularly with regard to existing depression and anxiety symptoms.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Medical history, physical examination, completing questionnaires, data collection for people with glioblastoma (gbm). The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTMedical history, physical examination, completing questionnaires, data collection

Medical history Physical examination Completion of validated questionnaires: * Suicide Scale (SSEV) * Patient Health Questionnaire-8 (PHQ-8) * Generalized Anxiety Disorder-7 (GAD-7) * EORTC-QLQ-30 * EORTC-QLQ-BN-20 * Short questionnaire on social support for chronic illnesses (SUCE-4) Data collection from medical records

Locations(6)

Charite

Berlin, Germany

University Hospital Knappschaftskrankenhaus Bochum

Bochum, Germany

University Hospital Essen

Essen, Germany

University hospital Hamburg Eppendorf

Hamburg, Germany

University hospital Heidelberg

Heidelberg, Germany

University hospital Muenster

Münster, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07409584

Related Trials

The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma

NCT068507662 locations

Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma

NCT076488232 locations

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

NCT0732656613 locations

Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma

NCT073461442 locations

Music Therapy in Newly Diagnosed Glioblastoma After Chemoradiation Therapy (MELODY-GBM)

NCT073759921 location